Partial ORF1ab Gene Target Failure with Omicron BA.2.12.1

Mutations in the genome of SARS-CoV-2 can affect the performance of molecular diagnostic assays. In some cases, such as S-gene target failure, the impact can serve as a unique indicator of a particular SARS-CoV-2 variant and provide a method for rapid detection. Here, we describe partial ORF1ab gene...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of clinical microbiology 2022-06, Vol.60 (6), p.e0060022-e0060022
Hauptverfasser: Rodino, Kyle G, Peaper, David R, Kelly, Brendan J, Bushman, Frederic, Marques, Andrew, Adhikari, Hriju, Tu, Zheng Jin, Marrero Rolon, Rebecca, Westblade, Lars F, Green, Daniel A, Berry, Gregory J, Wu, Fann, Annavajhala, Medini K, Uhlemann, Anne-Catrin, Parikh, Bijal A, McMillen, Tracy, Jani, Krupa, Babady, N Esther, Hahn, Anne M, Koch, Robert T, Grubaugh, Nathan D, Rhoads, Daniel D
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Mutations in the genome of SARS-CoV-2 can affect the performance of molecular diagnostic assays. In some cases, such as S-gene target failure, the impact can serve as a unique indicator of a particular SARS-CoV-2 variant and provide a method for rapid detection. Here, we describe partial ORF1ab gene target failure (pOGTF) on the cobas SARS-CoV-2 assays, defined by a ≥2-thermocycle delay in detection of the ORF1ab gene compared to that of the E-gene. We demonstrate that pOGTF is 98.6% sensitive and 99.9% specific for SARS-CoV-2 lineage BA.2.12.1, an emerging variant in the United States with spike L452Q and S704L mutations that may affect transmission, infectivity, and/or immune evasion. Increasing rates of pOGTF closely mirrored rates of BA.2.12.1 sequences uploaded to public databases, and, importantly, increasing local rates of pOGTF also mirrored increasing overall test positivity. Use of pOGTF as a proxy for BA.2.12.1 provides faster tracking of the variant than whole-genome sequencing and can benefit laboratories without sequencing capabilities.
ISSN:0095-1137
1098-660X
DOI:10.1128/jcm.00600-22